Golimumab could soon be approved

4th May 2011

The National Institute of Health and Clinical Excellence (NICE) issued its final guidance recommending the anti-TNF therapy golimumab for use for psoriatic arthritis.

NICE has added golimumab, which has the brand name Simponi, to its list of recommended treatments for the condition. It works by preventing the molecule tumour necrosis factor (TNF) from binding to receptors and causing inflammation. It suggested that the treatment is a viable option for adult patients with active and progressive psoriatic arthritis if it is used in a similar way to other TNF-inhibiting treatments, such as etanercept, infliximab and adalimumab.